5 results match your criteria: "University of California at San Francisco Cancer Center[Affiliation]"
Cytometry A
October 2005
University of California at San Francisco Cancer Center, San Francisco, California, USA.
Background: Representational oligonucleotide microarray analysis has been developed for detection of single nucleotide polymorphisms and/or for genome copy number changes. In this process, the intensity of hybridization to oligonucleotides arrays is increased by hybridizing a polymerase chain reaction (PCR)-amplified representation of reduced genomic complexity. However, hybridization to some oligonucleotides is not sufficiently high to allow precise analysis of that portion of the genome.
View Article and Find Full Text PDFCurr Oncol Rep
September 2004
Averback Melanoma Laboratory, University of California at San Francisco Cancer Center, 1600 Divisadero Street, Second Floor, Box 1706, San Francisco, CA 94115, USA.
Sophisticated molecular techniques that have recently become available permit analysis of genome-wide changes in gene copy number (DNA) or expression (RNA). These genomic strategies have the potential to transform our view of cancer biology and pathogenesis. This review surveys the studies performed using genome-wide analyses of melanoma, primarily in patient specimens but also in selected experimental models of melanoma.
View Article and Find Full Text PDFJ Neurosurg
March 2003
Brain Tumor Research Center, Department of Neurological Surgery, and the University of California at San Francisco Cancer Center, University of California at San Francisco, California 94115, USA.
Object: Temozolomide (TMZ)-induced O6-methylguanine (MG) DNA lesions, if not removed by MG-DNA methyltransferase (MGMT), mispair with thymine, trigger rounds of futile mismatch repair (MMR), and in glioma cells lead to prolonged G2-M arrest and ultimately cell death. Depletion of MGMT by O6-benzylguanine (BG) sensitizes tumor cells to TMZ, and this combination is currently used in clinical trials. The use of the TMZ+BG combination in gliomas, however, is complicated by the prolonged TMZ-induced G2-M arrest, which may delay activation of poorly defined cell death pathways and allow for MGMT repletion and reversal of toxicity.
View Article and Find Full Text PDFMol Cell Biol
September 2002
University of California at San Francisco Cancer Center, San Francisco, California 94143-0128, USA.
c-Myc promotes apoptosis by destabilizing mitochondrial integrity, leading to the release of proapoptotic effectors including holocytochrome c. Candidate mediators of c-Myc in this process are the proapoptotic members of the Bcl-2 family. We show here that fibroblasts lacking Bak remain susceptible to c-Myc-induced apoptosis whereas bax-deficient fibroblasts are resistant.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
March 2002
Auerback Melanoma Research Laboratory, Cutaneous Oncology Program, University of California at San Francisco Cancer Center and Department of Dermatology, University of California, San Francisco, CA 94115, USA.
To date, functional genomic studies have been confined to either cell-based assays or germline mutations, using transgenic or knockout animals. However, these approaches are often unable either to recapitulate complex biologic phenotypes, such as tumor metastasis, or to identify the specific genes and functional pathways that produce serious diseases in adult animals. Although the transcription factor NF-kappaB transactivates many metastasis-related genes in cells, the precise genes and functional-pathways through which NF-kappaB regulates metastasis in tumor-bearing hosts are poorly understood.
View Article and Find Full Text PDF